References
- Im AP, Sehgal AR, Carroll MP, et al. DNMT3a and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies. Leukemia. 2014;28(9):1774–1783.
- Abbas S, Lugthart S, Kavelaars FG, et al. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. Blood. 2010;116(12):2122–2126.
- Marcucci G, Maharry K, Wu YZ, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol. 2010;28(14):2348–2355.
- Paschka P, Schlenk RF, Gaidzik VI, et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol. 2010;28(22):3636–3643.
- Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209–2221.
- Patel JP, Gonen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366(12):1079–1089.
- Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462(7274):739–744.
- Xu W, Yang H, Liu Y, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell. 2011;19(1):17–30.
- Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010;18(6):553–567.
- Pirozzi CJ, Reitman ZJ, Yan H. Releasing the block: setting differentiation free with mutant idh inhibitors. Cancer Cell. 2013;23(5):570–572.
- Shih AH, Shank KR, Meydan C, et al. AG-221, a small molecule mutant IDH2 inhibitor, remodels the epigenetic state of IDH2-mutant cells and induces alterations in self-renewal/differentiation in IDH2-mutant aml model in vivo. Blood. 2014;124(21):437–437.
- Stein EM, DiNardo C, Altman JK, et al. Safety and efficacy of AG-221, a potent inhibitor of mutant IDH2 that promotes differentiation of myeloid cells in patients with advanced hematologic malignancies: results of a phase 1/2 trial. Blood. 2015;126(23):323–323.
- Agios Pharmaceuticals. Agios announces new clinical data from dose-escalation portion of phase 1 trials of single agent AG-120 showing durable molecular reponses in patients with advanced hematological malignancies [Press Release]. 2016. Available from http://investor.agios.com/phoenix.zhtml?c=251862&p=irol-newsArticle&ID=2058807
- Courtney DD, Schimmer AD, Yee KWL, et al. A phase I study of IDH305 in patients with advanced malignancies including relapsed/refractory AML and MDS that harbor IDH1r132 mutations. American society of Hematology meeting; 2016 Dec. Abstract # 1073.
- Agios Pharmaceuticals. Agios Pharmaceuticals selects third novel IDH mutant inhibitor, AG-881, for clinical development [Press release]. 2015. Available from http://investor.agios.com/phoenix.zhtml?c=251862&p=irol-newsArticle&ID=2041339
- Pollyea DADC, Thirman MJ, Letai A, et al. Results of a phase 1b study of venetoclax plus decitabine or azacitidine in untreated acute myeloid leukemia patients ≥65 years ineligible for standard induction therapy. J Clin Oncol. 2016;34(Suppl):Abstract 7009.
- Emadi A, Jun SA, Tsukamoto T, et al. Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations. Exp Hematol. 2014;42(4):247–251.
- Sarry J-E, Boutzen H, Récher C. A novel path for ATRA differentiation therapy in acute myeloid leukemia with isocitrate dehydrogenase mutations. Blood. 2014;124(21):3727–3727.
- Helena Boutzen ES, Cathebras M, Larrue C, et al. The combination of atra and dasatinib for differentiation therapy in acute myeloid leukemias with IDH mutations. Blood. 2015;126:2542 (abstract).
- Chen C, Liu Y, Lu C, et al. Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to BRD4 inhibition. Genes Dev. 2013;27(18):1974–1985.
- Sulkowski PL, Corso CD, Robinson ND, et al. 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces parp inhibitor sensitivity. Sci Transl Med. 2017;9(375):eaal2463.
- Chris Benton FR, Andreeff M, Kadia T, et al. Marina Konopleva: case series of AML patients receiving hypomethylation therapy and retrospectively found to have IDH1 or IDH2 mutations. Leuk Lymphoma. 2014 Jun;55(6):1431–1434.